Merck Moves To Refuel Hypertensive Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The company gains exclusive rights to NicOx’ nitric oxide-donating technology for use with systemic hypertension treatments.
You may also be interested in...
Pfizer Sees No Future In NicOx Glaucoma Candidate After Failure In Japanese Phase II Trial
Collaboration turns to diabetic retinopathy after Pfizer backs away from PF-03187207 development.
Pfizer Sees No Future In NicOx Glaucoma Candidate After Failure In Japanese Phase II Trial
Collaboration turns to diabetic retinopathy after Pfizer backs away from PF-03187207 development.
Pfizer Drops Phase II Glaucoma Candidate
Drug maker remains committed to joint research program with NicOx, however, and will proceed with follow-up compounds.